Table 1—

Baseline characteristics of study population

All patientsNonhypoglycaemic≥4.4 mmol·L−1 (≥79.0 mg·dL−1)Hypoglycaemic<4.4 mmol·L−1 (<79.0 mg·dL−1)p-value#Admission glucose
Subdivisions of hypoglycaemic groupp-value
Mild3.9–4.39mmol·L−1 (70–78.9mg·dL−1)Moderate3.4–3.89mmol·L−1 (61–69.9 mg·dL−1)Severe<3.4 mmol·L−1 (<61.0 mg·dL−1)
Subjects n105099357331311
Males49.750.242.10.2854.523.127.30.081
Age yrs67 (51–78)67 (51–78)62 (52–75)0.1358 (56–64)58 (49–68)76 (50–79)0.24
Congestive cardiac failure19.219.514.00.3912.115.418.20.87
Cerebrovascular disease10.911.08.70.839.17.79.10.99
Diabetes mellitus10.110.28.70.8312.17.700.46
Chronic renal impairment5.65.48.70.259.17.79.10.99
Chronic liver disease5.04.95.30.763.015.400.16
COPD20.220.415.80.5015.223.19.10.64
Confusion13.712.928.10.00115.238.554.50.03
Temperature <35°C or >40°C2.22.13.50.480018.20.013
Cardiac frequency >125 beats·min−113.312.429.8<0.000112.146.263.60.002
Respiratory frequency >30 breaths·min−136.035.347.40.06648.561.527.30.24
Haematocrit <30%4.34.41.80.33009.10.12
Systolic BP <90mmHg11.410.822.80.00512.138.536.40.08
pH <7.3513.012.031.6<0.000124.223.163.60.04
Blood urea >10.7 mmol·L−120.519.143.9<0.000139.446.254.50.70
Sodium <130 mEq·L−18.98.614.00.169.130.89.10.14
Pa,O2 >60 mmHg40.640.149.10.1836.461.572.70.067
Statin use24.024.614.00.0721.209.10.15
Oral hypoglycaemic use4.84.91.80.27003.00.74
PSI risk class >344.943.564.90.00257.676.972.70.39
CURB65 ≥332.130.852.60.00139.476.963.60.052
  • Data presented as median (interquartile range) or %, unless otherwise stated. COPD: chronic obstructive pulmonary disease; BP: blood pressure; Pa,O2: arterial oxygen tension; PSI: Pneumonia Severity Index; CURB65: confusion, urea level >7 mmol·L−1, respiratory frequency ≥30 breaths·min−1; blood pressure (systolic <90 mmHg or diastolic ≤60 mmHg), aged ≥65 yrs. #: compares hypoglycaemic patients with nonhypoglycaemic; : compares subdivisions of hypoglycaemic group.